Unknown

Dataset Information

0

Structure-based virtual screening and identification of a novel androgen receptor antagonist.


ABSTRACT: Hormonal therapies, mainly combinations of anti-androgens and androgen deprivation, have been the mainstay treatment for advanced prostate cancer because the androgen-androgen receptor (AR) system plays a pivotal role in the development and progression of prostate cancers. However, the emergence of androgen resistance, largely due to inefficient anti-hormone action, limits the therapeutic usefulness of these therapies. Here, we report that 6-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(6-methylpyridin-2-yl)nicotinamide (DIMN) acts as a novel anti-androgenic compound that may be effective in the treatment of both androgen-dependent and androgen-independent prostate cancers. Through AR structure-based virtual screening using the FlexX docking model, fifty-four compounds were selected and further screened for AR antagonism via cell-based tests. One compound, DIMN, showed an antagonistic effect specific to AR with comparable potency to that of the classical AR antagonists, hydroxyflutamide and bicalutamide. Consistent with their anti-androgenic activity, DIMN inhibited the growth of androgen-dependent LNCaP prostate cancer cells. Interestingly, the compound also suppressed the growth of androgen-independent C4-2 and CWR22rv prostate cancer cells, which express a functional AR, but did not suppress the growth of the AR-negative prostate cancer cells PPC-1, DU145, and R3327-AT3.1. Taken together, the results suggest that the synthetic compound DIMN is a novel anti-androgen and strong candidate for useful therapeutic agent against early stage to advanced prostate cancer.

SUBMITTER: Song CH 

PROVIDER: S-EPMC3436320 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-based virtual screening and identification of a novel androgen receptor antagonist.

Song Chin-Hee CH   Yang Su Hui SH   Park Eunsook E   Cho Suk Hee SH   Gong Eun-Yeung EY   Khadka Daulat Bikram DB   Cho Won-Jea WJ   Lee Keesook K  

The Journal of biological chemistry 20120713 36


Hormonal therapies, mainly combinations of anti-androgens and androgen deprivation, have been the mainstay treatment for advanced prostate cancer because the androgen-androgen receptor (AR) system plays a pivotal role in the development and progression of prostate cancers. However, the emergence of androgen resistance, largely due to inefficient anti-hormone action, limits the therapeutic usefulness of these therapies. Here, we report that 6-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(6-methylpyridin-2  ...[more]

Similar Datasets

| S-EPMC9877316 | biostudies-literature
| S-EPMC6411960 | biostudies-literature
| S-EPMC4248348 | biostudies-literature
| S-EPMC6017386 | biostudies-literature
| S-EPMC5331419 | biostudies-literature
| S-EPMC3124790 | biostudies-literature
| S-EPMC7671205 | biostudies-literature
| S-EPMC2812898 | biostudies-literature
| S-EPMC4056858 | biostudies-literature
| S-EPMC9052855 | biostudies-literature